➤ Subscribe for Complete Access

Flexible subscription options to meet your unique needs…

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Medtronic
Colorcon
Moodys
Express Scripts

Last Updated: November 27, 2021

DrugPatentWatch Database Preview

Patent: 8,840,888

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,840,888
Title:Dosage regimen for administering a CD19XCD3 bispecific antibody
Abstract: Provided herein is a method for assessing the risk of potential adverse effects for a human patient mediated by the administration of a CD19.times.CD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient, wherein a ratio of about 1:5 or lower is indicative for a risk of potential adverse effects for said patient.
Inventor(s): Nagorsen; Dirk (Munich, DE), Kufer; Peter (Munich, DE), Zugmaier; Gerhard (Munich, DE), Baeuerle; Patrick (Munich, DE)
Assignee: Micromet AG (Munich, DE)
Application Number:13/504,665
Patent Claims:see list of patent claims

Details for Patent 8,840,888

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Amgen, Inc. BLINCYTO blinatumomab For Injection 125557 2014-12-03 ⤷  Try it Free 2029-10-27
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Colorcon
Moodys
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.